Erica Smith, VP of Business Development, discusses the benefits of the Placebell©™ approach in video interview at Biotech Showcase in San Francisco, CA.
Date: January, 2019
Placebo Response
Dominique Demolle, CEO speaks with Andy Burrows of PCT TV about the early vision and development of Placebell©™ at Partnerships in Clinical Trials, Europe
In analgesia randomized clinical trials (RCTs), the magnitude of the placebo response has a negative influence when testing the statistically significant superiority of active compounds compared to placebo.
In analgesia randomized clinical trials (RCTs), the magnitude and the variability of the placebo response have a negative influence when testing the statistically significant superiority of active compounds compared to placebo.
The placebo response exerts a confusing influence when testing the statistically significant superiority of active compounds compared to placebo in analgesia randomized clinical trials (RCTs). Furthermore, the magnitude of this effect has tended to increase over time with the year of trial completion, including in neuropathic pain trials.
In analgesia randomized clinical trials (RCTs), the magnitude of the placebo response tends to increase with the year of trial completion, including in neuropathic pain trials.